Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients.

Next Previous
Trial Profile

A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 16 May 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rufinamide (Primary)
  • Indications Lennox-Gastaut syndrome
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Eisai Co Ltd

    • Most Recent Events

    • 27 Apr 2018 Results from NCT01151540, NCT01405053, NCT01146951 and 2 other studies, presented at the 70th Annual Meeting of the American Academy of Neurology
    • 21 Apr 2016 Post-hoc subgroup analysis (n=31) of this trial were presented at the 68th Annual Meeting of the American Academy of Neurology.
    • 08 Mar 2012 Actual end date (Aug 2011) added as reported by ClinicalTrials.gov (Parent trial:NCT01146951).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top